Clinical Biochemistry Laboratory, Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia/UFBA, Salvador, Bahia, Brazil.
Clinical Toxicology Laboratory, Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia/UFBA, Salvador, Bahia, Brazil.
Curr Drug Res Rev. 2021;13(2):86-89. doi: 10.2174/2589977513666210127094222.
Naltrexone (NTX) is an opioid antagonist that inhibits cell proliferation in vivo when administered in low doses. Naltrexone in low doses can reduce tumor growth by interfering with cell signalling as well as by modifying the immune system. It acts as an Opioid Growth Factor receptor (OGFr) antagonist and the OGF-OGFr axis is an inhibitory biological pathway present in human cancer cells and tissues, being a target for the treatment with naltrexone low-dose (LDN). Clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors. LDN shows promising results for people with primary cancer of the bladder, breast, liver, lung, lymph nodes, colon and rectum. This short review provides further evidence to support the role of LDN as an anticancer agent.
纳曲酮（NTX）是一种阿片类拮抗剂，低剂量给药时可抑制体内细胞增殖。低剂量的纳曲酮可以通过干扰细胞信号以及改变免疫系统来减少肿瘤生长。它作为阿片样生长因子受体（OGFr）拮抗剂，OGF-OGFr 轴是存在于人类癌细胞和组织中的抑制性生物途径，是纳曲酮低剂量（LDN）治疗的靶点。临床试验提出了一种独特的机制，使 LDN 能够影响肿瘤。LDN 对膀胱癌、乳腺癌、肝癌、肺癌、淋巴结、结肠和直肠癌的原发性癌症患者显示出有前景的结果。这篇简短的综述提供了进一步的证据，支持 LDN 作为一种抗癌药物的作用。
